ZFIN Fish: gz15Tg

ZFIN ID: ZDB-FISH-150901-2166

ZFIN ID: ZDB-FISH-150901-2166

Fish name:	gz15Tg
Genotype:	gz15Tg
Targeting Reagent:	none

HUMAN DISEASE MODELED by gz15Tg

Human Disease	Conditions	Citations
non-alcoholic fatty liver disease	chemical treatment by diet: cholesterol	Yan et al., 2017
	chemical treatment by diet: fructose	Yan et al., 2017

GENE EXPRESSION
Gene expression in gz15Tg

RNA expression

Expressed Gene	Structure	Conditions	Figures
anxa4	intrahepatic bile duct liver	standard conditions	Fig. 4 from Zhang et al., 2014
cebpa	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
dnmt1	exocrine pancreas intestinal bulb intestine	standard conditions	Fig. 3 , Fig. 5 from Anderson et al., 2009
htr2b	female organism hepatocyte male organism hepatocyte	standard conditions	Fig. 3 from Yang et al., 2017
il1b	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
lepa	hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
nfkb2	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
pparg	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
prox1a	liver hepatocyte	standard conditions	Fig. 4 from Zhang et al., 2017
srebf1	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
tgfb1a	hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
tnfa	hepatocyte	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017

Protein expression

Antibody	Antigen Genes	Structure	Conditions	Figures
Ab-2F11		gall bladder hepatic duct intrahepatic bile duct liver pancreatic duct	standard conditions	Fig. 4 from Zhang et al., 2014 Fig. 2 from Curado et al., 2010 Fig. 3 from Noël et al., 2008 Fig. 1, Fig. 3 from Dong et al., 2007
Ab2-lepa		hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
Ab6-pcna		liver	chemical treatment: doxycycline	Fig. 4 from Yan et al., 2017
Ab1-tgfb1a		hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
ab1-sst		endocrine pancreas	standard conditions	Fig. 1 from Dong et al., 2007
Ab29-mapk		hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
Ab4-tjp1		hepatocyte apical junction complex	standard conditions	Fig. 4 from Zhang et al., 2017
Ab7-h3		intestine pancreas	standard conditions	Fig. 5 from Anderson et al., 2009
Ab-WCL15		intrahepatic bile duct macrophage	standard conditions	Fig. 2, Fig. 3 from Curado et al., 2010
Ab5-pcna		liver	chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate	Fig. 5 from Yan et al., 2015
Ab1-casp3		liver	chemical treatment: FPR A14, chemical treatment: doxycycline monohydrate	Fig. 5 from Yan et al., 2015
Ab-smad2		hepatocyte	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
Ab1-pan-Cadherin		digestive system plasma membrane	standard conditions	Fig. 1 from Dong et al., 2008
Ab1-dnmt1	dnmt1	exocrine pancreas intestinal bulb intestine	standard conditions	Fig. 3 , Fig. 5 from Anderson et al., 2009
Ab3-prox1	prox1a	liver hepatocyte	standard conditions	Fig. 4 from Zhang et al., 2017

Reporter gene expression

Expressed Gene	Structure	Conditions	Figures
DsRed	hepatocyte liver	control	34 figures from 23 publications
	female organism liver hepatocyte (not) liver male organism liver	chemical treatment: pharmaceutical	11 figures from 6 publications
EGFP	exocrine pancreas gut pancreas pancreatic acinar cell unspecified	control	17 figures from 12 publications
	exocrine pancreas pancreatic acinar cell	chemical treatment: sodium valproate	Fig. 6 from Navis et al., 2015 Fig. 1 from Farooq et al., 2008
GFP	endocrine pancreas exocrine pancreas	standard conditions	Fig. 2 from Zhai et al., 2017 Fig. 1 from Dong et al., 2008 Fig. 1, Fig. 3 from Dong et al., 2007
RFP	endocrine pancreas pancreatic B cell liver	control	Fig. S1 from Bagnat et al., 2010 Fig. 1 , Fig. 2 , Fig. 3 from Anderson et al., 2009

PHENOTYPE
Phenotype in gz15Tg

Phenotype	Conditions	Figures
cleithrum bone mineralization increased occurrence, abnormal	chemical treatment by environment: osteogenesis regulator	Fig. 6 from Bae et al., 2017
hepatocyte ab-smad2 labeling amount, ameliorated	chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor	Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling amount, ameliorated	chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor	Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling amount, ameliorated	chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor	Fig. 2 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal	chemical treatment by diet: cholesterol, chemical treatment: STAT3 inhibitor	Fig. 2 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal	chemical treatment by diet: cholesterol, chemical treatment: LY294002	Fig. 2 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte tgfb1a expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal	chemical treatment by diet: cholesterol, chemical treatment: LY294002	Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal	chemical treatment by diet: cholesterol, chemical treatment: LY294002	Fig. 2 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal	chemical treatment by diet: cholesterol, chemical treatment: LY294002	Fig. 2 from Yan et al., 2017
hepatocyte tnfa expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 2 from Yan et al., 2017
hepatocyte Ab2-lepa labeling increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte srebf1 expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte il1b expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte tgfb1a expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 2 from Yan et al., 2017
hepatocyte lepa expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte lepa expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 2 from Yan et al., 2017
hepatocyte Ab29-mapk labeling increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte nfkb2 expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte ab1-tgfb1a labeling increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 2 from Yan et al., 2017
hepatocyte cebpa expression increased amount, abnormal	chemical treatment by diet: glucose	Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
hepatocyte pparg expression increased amount, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte ab-smad2 labeling increased amount, abnormal	chemical treatment by diet: fructose	Fig. 2 from Yan et al., 2017
hepatocyte inflammatory response increased process quality, abnormal	chemical treatment by diet: fructose	Fig. 1 from Yan et al., 2017
hepatocyte inflammatory response increased process quality, abnormal	chemical treatment by diet: cholesterol	Fig. 1 from Yan et al., 2017
liver increased size, abnormal	chemical treatment: ethanol	Fig. 1 from Tsedensodnom et al., 2013
liver mislocalised, abnormal	chemical treatment: SU5402	Fig. 6 from Qian et al., 2013
liver mislocalised, abnormal	chemical treatment: all-trans-retinoic acid	Fig. 6 from Qian et al., 2013
male organism hepatocyte htr2b expression increased amount, abnormal	standard conditions	Fig. 3 from Yang et al., 2017
Meckel's cartilage bone mineralization increased occurrence, abnormal	chemical treatment by environment: osteogenesis regulator	Fig. 6 from Bae et al., 2017
palatoquadrate arch bone mineralization increased occurrence, abnormal	chemical treatment by environment: osteogenesis regulator	Fig. 6 from Bae et al., 2017
pericardium edematous, abnormal	chemical treatment: ethanol	Fig. 1 from Tsedensodnom et al., 2013
trunk curved dorsal, abnormal	chemical treatment: ethanol	Fig. 1 from Tsedensodnom et al., 2013
vertebra bone mineralization increased occurrence, abnormal	chemical treatment by environment: osteogenesis regulator	Fig. 6 from Bae et al., 2017

CITATIONS (57)